Sorafenib 200mgTablet
Anti-Cancer

Sorafenib 200mg

Sorafenib Tosylate

Soranib (Sorafenib 200mg) is an oral anti-cancer medicine that works by blocking abnormal protein signals that cause cancer cells to multiply. It helps stop or slow the spread of cancer in hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. Available for global pharmaceutical export with WHO-GMP certification.

Strengths

200mg

Packing

120 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Sorafenib Tosylate 200mg
Dosage Form
Tablet
Available Strengths
200mg
Packing
120 tablets/bottle
Route of Administration
Oral
Dosage
400mg (two 200mg tablets) twice daily on an empty stomach
Indications
Advanced renal cell carcinoma, unresectable hepatocellular carcinoma, locally recurrent or metastatic differentiated thyroid carcinoma
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 25°C in a dry place, protected from moisture
Shelf Life
36 months
Side Effects
Diarrhea, fatigue, hand-foot skin reaction, rash, hypertension, alopecia, nausea
Precautions
Monitor blood pressure regularly; liver function tests recommended; avoid in pregnancy; dose adjustment in hepatic impairment

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Lenalidomide 25mgCapsule

Lenalidomide 25mg

Lenalidomide

Lenalid (Lenalidomide 25mg) is an anti-cancer medicine that works by enhancing the immune system to attack cancer cells while preventing growth of new blood vessels within tumors. It is used for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Available in 5mg, 10mg, and 25mg capsule strengths for global pharmaceutical export.

5mg / 10mg / 25mg
Imatinib 400mgTablet

Imatinib 400mg

Imatinib Mesylate

First-in-class BCR-ABL tyrosine kinase inhibitor that transformed CML from a fatal disease into a chronically manageable condition, achieving complete cytogenetic response in over 80% of newly diagnosed chronic-phase patients. It also targets c-KIT and PDGFR, making it the standard first-line treatment for unresectable or metastatic GIST and Ph+ ALL. Cipla and Sun Pharma manufacture affordable Indian generics in both 100mg and 400mg tablet strengths exported to oncology programmes worldwide.

100mg / 400mg
Erlotinib 150mgTablet

Erlotinib 150mg

Erlotinib Hydrochloride

First-generation EGFR tyrosine kinase inhibitor that competitively blocks ATP binding to EGFR, suppressing downstream RAS-MAPK and PI3K-AKT tumour survival signalling in EGFR-mutant NSCLC. It is also approved at 100mg in combination with gemcitabine for locally advanced or metastatic pancreatic cancer, where it provides a modest but statistically significant survival benefit. Cipla and Glenmark supply export-quality generics in 100mg and 150mg tablets as affordable alternatives to Tarceva.

100mg / 150mg

Need bulk pricing for Sorafenib 200mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote